期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 132, 期 1, 页码 101-109出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2013.05.013
关键词
Chronic idiopathic urticaria; chronic spontaneous urticaria; H-1-antihistamine; H-2-antihistamines; hive; itch; leukotriene receptor antagonist; omalizumab; pruritus; wheal
资金
- Genentech, Inc, South San Francisco, Calif
- Novartis Pharma AG, Basel, Switzerland
- Genentech, Inc
- Teva
- Forest
- Merck
- Viropharma
- South Carolina Allergy and Immunology Society
- Meda Pharmaceutical
- Novartis
- Allergopharma
- Thermo Fischer Scientific
- Jansen Cilag
- Stallergenes
- ALK-Abello
- Allergies Therapeutics
- Novartis Poland
- AstraZeneca
- GlaxoSmithKline
- Boehringer Ingelheim
- Adamed
- Hal
- FAES
- Chiesi
- Merck Sharp and Dohme
- Alcon
- Allergan
- Sunovion
Background: Patients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) often continue to experience symptoms despite receiving standard-of-care therapy with H-1-antihistamines along with 1 or more add-on therapies. Objectives: We sought to evaluate the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent CIU/CSU despite treatment with H-1-antihistamines at up to 4 times the approved dose plus H-2-antihistamines, leukotriene receptor antagonists, or both. Methods: In this phase III study patients were randomized to receive 6 subcutaneous injections at 4-week intervals of either 300 mg of omalizumab or placebo, followed by a 16-week observation period. The primary objective of the study was to evaluate the overall safety of omalizumab compared with placebo. Efficacy (itch severity, hive, and urticaria activity scores) was evaluated at weeks 12 and 24. Results: The overall incidence and severity of adverse events and serious adverse events were similar between omalizumab and placebo recipients; the safety profile was consistent with omalizumab in patients with allergic asthma. At week 12, the mean change from baseline in weekly itch severity score was -8.6 (95% CI, -9.3 to -7.8) in the omalizumab group compared with -4.0 (95% CI, -5.3 to -2.7) in the placebo group (P < .001). Significant improvements were seen for additional efficacy end points at week 12; these benefits were sustained to week 24. Conclusion: Omalizumab was well tolerated and reduced the signs and symptoms of CIU/CSU in patients who remained symptomatic despite the use of H-1-antihistamines (up to 4 times the approved dose) plus H-2-antihistamines, leukotriene receptor antagonists, or both.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据